| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d340162ad84b134af15e55b7011ead8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8dba9c8532bccbd23c884ebdcf7ce1cd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-31 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 |
| filingDate |
2005-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bfec5f12d29c1fa276ba8302b81bf23 |
| publicationDate |
2006-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006063465-A1 |
| titleOfInvention |
Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists |
| abstract |
The present invention provides the use of somatostatin antagonists for treating and preventing hepatic insulin sensitizing substance (HΙSS)-dependent insulin resistance (HDIR) and hemorrhage induced insulin resistance. The present invention further provides pharmaceutical compositions comprising a somatostatin antagonist and a pharmaceutically acceptable liver targetting compound. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11078259-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7939661-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008031735-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7862825-B2 |
| priorityDate |
2004-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |